Companies / RHY

RHYTHM BIOSCIENCES LIMITED

ASX:RHYHealth Care Equipment & Services
353.9M shares on issueASX (delayed) · as of 28 July 2026$0.080price · delayed$31.8Mmarket cap · indicative
D
Dilution grade

Share count grew 42% in 24 months; runway 2–4 quarters; 5 cash raises in 24 months

Cash runway3.5 quarters of funding
Share-count growth (24m)42.3%
Raise cadence (24m)5 cash raises
Options & rights overhang46.9% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

RHYTHM BIOSCIENCES LIMITED's ordinary share count grew 42.3% between May 2024 and April 2026, to 354M shares. The company raised capital five times in that 24-month window for total disclosed proceeds of A$12.5M, most recently raising A$5.3M in February 2026. Options and rights on issue could convert into 166M new shares, equal to 46.9% of the current share count, with none currently in the money and the nearest expiry in August 2026. At the March 2026 quarter the company reported A$4.8M in available cash, representing about 3.5 quarters of funding at its reported burn rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
46.9%
Max option dilution
0.0%
ITM option dilution
3
Raises · last 12 months
3.5 qtrs
Cash cover · 2–4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 353.9M per ASX (delayed) (28 July 2026).
298.4M318.7M339.1MDec 24Sept 25July 26Cash raise · 20 Feb 2026Cash raise · 16 Sept 2025Cash raise · 13 Aug 2025Cash raise · 29 May 2025

Cash runway

3.5 qtrs
Two to four quarters of funding at the recent spend rate.
$4.8M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
17 Apr 20262A · quoted issueRHY : ORDINARY FULLY PAID353.9MAppendix 2A
15 Apr 20262A · quoted issueRHY : ORDINARY FULLY PAID353.9MAppendix 2A
7 Apr 20263H · cancellationRHY : ORDINARY FULLY PAID330.2MAppendix 3H
2 Apr 20262A · quoted issueRHY : ORDINARY FULLY PAID332.1MAppendix 2A
27 Mar 20262A · quoted issueRHY : ORDINARY FULLY PAID333.1MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

5 cash raises in the last 24 months · 3 in the last 12 months

$5.3M
Capital raise
20 Feb 2026
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

46.9%
Total overhang · of current shares
0.0%
In the money · at current price
165.9M
Potential new shares
Aug 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
31 Mar 2026David AtkinsSell—2.0M—3Y notice
1 Dec 2025Gavin Fox-SmithOther1.0M1.0M—3Y notice
1 Dec 2025Sue MacLemanBuy450k450k—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

20 July 2026New Lung Cancer Genetype Risk Assessment Test
6 July 2026Accreditation Matters Conference Presentation
1 July 2026Rhythm launches tailored ColoSTAT marketing campaign
3 June 2026Rhythm Bio Singapore Investor Presentation
25 May 2026ColoSTAT Access Program Gains Momentum
13 May 2026Investor Presentation
5 May 2026ColoSTAT Demonstrates Early Clinical Adoption
5 May 2026Investor Webinar
29 Apr 2026$PQuarterly Activities Report and Appendix 4C
28 Apr 2026RHYO Underwriting Update
17 Apr 2026Application for quotation of securities - RHY
15 Apr 2026Cleansing Notice
15 Apr 2026Application for quotation of securities - RHY
14 Apr 2026$PResponse to ASX Query Letter
14 Apr 2026Completion Of RHYO Option Underwriting
7 Apr 2026Change of Director's Interest Notice
7 Apr 2026Notification of cessation of securities - RHY
2 Apr 2026Proposed issue of securities - RHY
2 Apr 2026Application for quotation of securities - RHY
30 Mar 2026RHYO Options Underwriting Agreement

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.